From platinum compounds to targeted therapies in advanced thoracic malignancies

Marko Jakopovic, Anish Thomas, Ariel Lopez-Chavez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Improved understanding of the molecular mechanisms involved in development, growth and spread of cancer have led to develpment of targeted therapies for many cancers. Based on their superior tolerability and efficacy, targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or crizotinib are preferred first-line treatments over platinum-based chemotherapies in patients whose tumours harbour EGFRactivating mutations and anaplastic lymphoma kinase (ALK) translocations, respectively. Active areas of research in EGFR-mutant and ALK-translocated NSCLC include identification of mechanisms of resistance and overcoming them. Therapeutic targeting of several other targets including ROS, RET and discoidin domain receptor 2 (DDR2) tyrosine kinases are in early phases of clinical evaluation. Despite the advances in tumour genomic sequencing, a substantial fraction of patients with non-small cell lung cancer (NSCLC) do not have any targetable genetic alteration. Ongoing research is focused on identifying mechanisms of carcinogenesis in these patients. Targeted therapies in small cell lung cancer (SCLC) and thymic malignancies have not yielded meaningful clinical benefits, and platinum-based therapies remain the cornerstone of treating patients with advanced disease.

Original languageEnglish (US)
Pages (from-to)477-482
Number of pages6
JournalAnticancer Research
Volume34
Issue number1
StatePublished - Jan 1 2014

Fingerprint

Platinum Compounds
Thorax
Neoplasms
Platinum
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Therapeutics
Small Cell Lung Carcinoma
Growth and Development
Research
Protein-Tyrosine Kinases
Carcinogenesis
Drug Therapy
Mutation

Keywords

  • Advanced thoracic malignancies
  • Platinum-based chemotherapy
  • Review
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Jakopovic, M., Thomas, A., & Lopez-Chavez, A. (2014). From platinum compounds to targeted therapies in advanced thoracic malignancies. Anticancer Research, 34(1), 477-482.

From platinum compounds to targeted therapies in advanced thoracic malignancies. / Jakopovic, Marko; Thomas, Anish; Lopez-Chavez, Ariel.

In: Anticancer Research, Vol. 34, No. 1, 01.01.2014, p. 477-482.

Research output: Contribution to journalArticle

Jakopovic, M, Thomas, A & Lopez-Chavez, A 2014, 'From platinum compounds to targeted therapies in advanced thoracic malignancies', Anticancer Research, vol. 34, no. 1, pp. 477-482.
Jakopovic M, Thomas A, Lopez-Chavez A. From platinum compounds to targeted therapies in advanced thoracic malignancies. Anticancer Research. 2014 Jan 1;34(1):477-482.
Jakopovic, Marko ; Thomas, Anish ; Lopez-Chavez, Ariel. / From platinum compounds to targeted therapies in advanced thoracic malignancies. In: Anticancer Research. 2014 ; Vol. 34, No. 1. pp. 477-482.
@article{60caf43041bc44e5bd999046219b1e3a,
title = "From platinum compounds to targeted therapies in advanced thoracic malignancies",
abstract = "Improved understanding of the molecular mechanisms involved in development, growth and spread of cancer have led to develpment of targeted therapies for many cancers. Based on their superior tolerability and efficacy, targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or crizotinib are preferred first-line treatments over platinum-based chemotherapies in patients whose tumours harbour EGFRactivating mutations and anaplastic lymphoma kinase (ALK) translocations, respectively. Active areas of research in EGFR-mutant and ALK-translocated NSCLC include identification of mechanisms of resistance and overcoming them. Therapeutic targeting of several other targets including ROS, RET and discoidin domain receptor 2 (DDR2) tyrosine kinases are in early phases of clinical evaluation. Despite the advances in tumour genomic sequencing, a substantial fraction of patients with non-small cell lung cancer (NSCLC) do not have any targetable genetic alteration. Ongoing research is focused on identifying mechanisms of carcinogenesis in these patients. Targeted therapies in small cell lung cancer (SCLC) and thymic malignancies have not yielded meaningful clinical benefits, and platinum-based therapies remain the cornerstone of treating patients with advanced disease.",
keywords = "Advanced thoracic malignancies, Platinum-based chemotherapy, Review, Targeted therapy",
author = "Marko Jakopovic and Anish Thomas and Ariel Lopez-Chavez",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "34",
pages = "477--482",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - From platinum compounds to targeted therapies in advanced thoracic malignancies

AU - Jakopovic, Marko

AU - Thomas, Anish

AU - Lopez-Chavez, Ariel

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Improved understanding of the molecular mechanisms involved in development, growth and spread of cancer have led to develpment of targeted therapies for many cancers. Based on their superior tolerability and efficacy, targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or crizotinib are preferred first-line treatments over platinum-based chemotherapies in patients whose tumours harbour EGFRactivating mutations and anaplastic lymphoma kinase (ALK) translocations, respectively. Active areas of research in EGFR-mutant and ALK-translocated NSCLC include identification of mechanisms of resistance and overcoming them. Therapeutic targeting of several other targets including ROS, RET and discoidin domain receptor 2 (DDR2) tyrosine kinases are in early phases of clinical evaluation. Despite the advances in tumour genomic sequencing, a substantial fraction of patients with non-small cell lung cancer (NSCLC) do not have any targetable genetic alteration. Ongoing research is focused on identifying mechanisms of carcinogenesis in these patients. Targeted therapies in small cell lung cancer (SCLC) and thymic malignancies have not yielded meaningful clinical benefits, and platinum-based therapies remain the cornerstone of treating patients with advanced disease.

AB - Improved understanding of the molecular mechanisms involved in development, growth and spread of cancer have led to develpment of targeted therapies for many cancers. Based on their superior tolerability and efficacy, targeted therapies with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) or crizotinib are preferred first-line treatments over platinum-based chemotherapies in patients whose tumours harbour EGFRactivating mutations and anaplastic lymphoma kinase (ALK) translocations, respectively. Active areas of research in EGFR-mutant and ALK-translocated NSCLC include identification of mechanisms of resistance and overcoming them. Therapeutic targeting of several other targets including ROS, RET and discoidin domain receptor 2 (DDR2) tyrosine kinases are in early phases of clinical evaluation. Despite the advances in tumour genomic sequencing, a substantial fraction of patients with non-small cell lung cancer (NSCLC) do not have any targetable genetic alteration. Ongoing research is focused on identifying mechanisms of carcinogenesis in these patients. Targeted therapies in small cell lung cancer (SCLC) and thymic malignancies have not yielded meaningful clinical benefits, and platinum-based therapies remain the cornerstone of treating patients with advanced disease.

KW - Advanced thoracic malignancies

KW - Platinum-based chemotherapy

KW - Review

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84897025995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897025995&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 477

EP - 482

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -